1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Surrogate end points in lymphoma
    Journal Article

    Batlevi, C. L.; Younes, A.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pharmacodynamic assessment in whole blood for the BET bromodomain inhibitor CPI-0610 of target engagement in patients with progressive lymphoma
    Meeting Abstract

    Mertz, J. A.; Blum, K. A.; Younes, A.; Abramson, J. S.; Maris, M. B.; Flinn, I. W.; Goy, A.; Borger, D. R.; Cooper, M. R.; Sims, R. J.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Clinical neurological features and electrographic patterns of patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel at Memorial Sloan Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Sequeira, A.; Mao, D.; Chen, X.; Avila, E.; Mead, E.; Sauter, C. S.; Palomba, M. L.; Dahi, P. B.; Batlevi, C. L.; Shah, G.; more...
    Neuro-Oncology (2018)

    Fulltext@MSK | Save
  • A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Younes, A.; Sehn, L. H.; Johnson, P.; Zinzani, P. L.; Hong, X.; Zhu, J.; Samoilova, O.; Suh, C.; Matsumura, I.; Lopez-Hernandez, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Long-term follow-up of SWOG S0816: Response-adapted therapy for stage III/IV Hodgkin lymphoma demonstrates limitations of PET-adapted approach
    Meeting Abstract

    Stephens, D. M.; Li, H.; Schoder, H.; Straus, D. J.; Moskowitz, C. H.; Leblanc, M. L.; Rimsza, L. M.; Bartlett, N. L.; Evens, A. M.; LaCasce, A. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study
    Meeting Abstract

    Sehn, L. H.; Herrera, A. F.; Matasar, M. J.; Kamdar, M.; Assouline, S.; Hertzberg, M.; Kim, T. M.; Kim, W. S.; McMillan, A.; Ozcan, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Atezolizumab in combination with obinutuzumab and lenalidomide demonstrates favorable activity and manageable toxicity in patients with relapsed/refractory follicular lymphoma (FL): An interim analysis of a phase Ib/II trial
    Meeting Abstract

    Salles, G.; Ghosh, N.; Lossos, I. S.; Palomba, M. L.; Mehta, A.; Casasnovas, O.; Stevens, D.; Abajo, A.; Nielsen, T.; Chitra, S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Survival for relapsed/refractory Hodgkin lymphoma patients with recurrent or persistent disease following autologous hematopoietic stem cell transplantation treated in the modern era
    Meeting Abstract

    Rajeeve, S.; Shah, G. L.; Moskowitz, C. H.; Moskowitz, A. J.
    Blood (2018)

    Fulltext@MSK | Save
  • Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: Preliminary results from the phase 2 CheckMate 436 trial
    Meeting Abstract

    Moskowitz, A. J.; Santoro, A.; Gritti, G.; Brice, P.; Cunningham, D.; Barr, P.; Kline, J.; Kuruvilla, J.; Johnson, N. A.; Mehta-Shah, N.; more...
    Blood (2018)

    Fulltext@MSK | Save